REGENXBIO · 3 months ago
Contract Clinical Systems Specialist
REGENXBIO is an exceptional place where some of the best and brightest people have the opportunity to collaborate on amazing science. As a Contract Clinical Systems Specialist, you will be responsible for clinical system maintenance and inspection readiness activities related to the Trial Master File (TMF) and Clinical Trial Management System (CTMS). You will work cross-functionally to support system setup, perform system quality checks, and manage inspection readiness issues.
BiopharmaBiotechnologyGeneticsTherapeutics
Responsibilities
Working cross-functionally to support system setup and customization as required
Performing eTMF inventory and document reviews per applicable study specific plans and procedures
Performing regular system quality checks and communicate compliance gaps to clinical trial team members, medical organization leadership, and any/all applicable stakeholders as needed
Working with Clinical System owners to manage inspection readiness issues to completion
Monitoring eCTMS completeness and accuracy and provide compliance status update to system managers/owners as needed
Supporting system data/document entry, including oversight of eTMF/eCTMS system directories (e.g. reference data repositories)
Monitoring system access and process user access requests
Participating in system related process improvement initiatives and standard document updates
Qualification
Required
Bachelor's degree with an emphasis on Life Sciences preferred
At least 5 year clinical research experience (or equivalent) handling/managing clinical system information (e.g. TMF documentation, eCTMS information, etc.)
Must have working knowledge of ICH/GCP principals and demonstrate a working knowledge of clinical trial execution
Must have experience with clinical trial IT systems such as electronic Trial Master File and/or electronic CTMS
Demonstrates familiarity with industry standards
Ability to work in a dynamic, fast paced, team environment
Company
REGENXBIO
REGENXBIO develops adeno-associated viral vector-based therapeutics and research tools, offering NAV, a recombinant AAV-vector.
Funding
Current Stage
Public CompanyTotal Funding
$928.19MKey Investors
Vivo Capital
2025-05-19Post Ipo Debt· $150M
2024-03-06Post Ipo Equity· $140M
2021-01-06Post Ipo Equity· $230.3M
Leadership Team
Recent News
2026-01-16
Longevity.Technology
2026-01-16
Company data provided by crunchbase